Meiji Seika Pharma Co., Ltd. announced that its subsidiary, KM Biologics Co., Ltd., has achieved the first technical milestone in its strategic collaboration with Serum Institute of India Pvt. Ltd. (SII) for the development and manufacturing of a Japanese Encephalitis (JE) vaccine.
The collaboration, governed by a comprehensive technology transfer agreement, marks a critical step in addressing the persistent public health challenge of Japanese Encephalitis in Asia. Following the successful achievement of this initial milestone, SII,the world’s largest vaccine manufacturer will formally commence development activities in India, utilizing the proven manufacturing processes and expertise cultivated by KM Biologics.
KM Biologics will provide the technical blueprint for its established JE vaccine, enabling local manufacturing in India.The partnership pairs KM Biologics’ advanced R&D and quality control expertise with SII’s unparalleled production capacity of 4 billion doses annually. The initiative aims to secure a stable, large-scale supply of affordable JE vaccines to support India’s national immunization programs and broader infectious disease control. This collaboration serves as a foundational pillar for Meiji Seika Pharma’s business expansion across the Global South, leveraging SII’s distribution network to improve health outcomes in over 170 countries.
“Contributing to global infectious disease control is a core mission for Meiji Seika Pharma and KM Biologics,” the company stated. “By collaborating with the Serum Institute of India, we are establishing a robust manufacturing framework to meet the high demand for Japanese Encephalitis vaccines and reinforce public health infrastructure across the region.”
Moving forward, both organizations will work in close coordination to finalize development and accelerate the establishment of a localized supply chain.
By Pragna Biswas
